5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

A. Ascierto, Paolo; Dréno, Brigitte; Larkin, James; Ribas, Antoni; Liszkay, Gabriella; Maio, Michele; Mandalà, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, L.; de la Cruz‐Merino, Luis; Atkinson, Victoria; Dutriaux, Caroline; Garbe, Claus; J. Hsu, Jessie; Bowen Jones, S.C.; Li, Haocheng; McKenna, Edward; Voulgari, Athina; A. McArthur, Grant

doi:10.1158/1078-0432.ccr-21-0809

Public

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Published in Clinical Cancer Research • Jun 22, 2021

Authors:

Paolo A. Ascierto

Brigitte Dréno

James Larkin

Abstract

PURPOSE: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation-positive advanced melanoma. We re...

Subject

Vemurafenib

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!